Who are Oral roflumilast's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Eucrisa, Roflumilast conventional dosage, metformin and roflumilast, Placebo-Apremilast, Roflumilast Foam, Roflumilast Foam 0.3%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/oral-roflumilast.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Oral roflumilast — Competitive Intelligence Brief

Oral roflumilast (Oral roflumilast) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Phosphodiesterase-4 (PDE-4) inhibitor. Area: Respiratory / Immunology.

phase 3 Phosphodiesterase-4 (PDE-4) inhibitor PDE-4 Respiratory / Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Oral roflumilast (Oral roflumilast) — The University of Hong Kong. Roflumilast is a phosphodiesterase-4 (PDE-4) inhibitor that reduces inflammation by increasing intracellular cAMP levels in immune and structural cells.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Oral roflumilast TARGET	Oral roflumilast	The University of Hong Kong	phase 3	Phosphodiesterase-4 (PDE-4) inhibitor	PDE-4
Eucrisa	Crisaborole	Anacor Pharms Inc	marketed	PDE-4 inhibitor	Phosphodiesterase 4 (PDE-4)	2016-01-01
Roflumilast conventional dosage	Roflumilast conventional dosage	Asan Medical Center	marketed	Phosphodiesterase-4 (PDE-4) inhibitor	PDE-4
metformin and roflumilast	metformin and roflumilast	University Medical Centre Ljubljana	marketed	Combination therapy: biguanide and phosphodiesterase-4 inhibitor	Metformin: mitochondrial glycerophosphate dehydrogenase; Roflumilast: phosphodiesterase-4 (PDE-4)
Placebo-Apremilast	Placebo-Apremilast	Amgen	marketed	Phosphodiesterase-4 (PDE-4) inhibitor	PDE-4
Roflumilast Foam	Roflumilast Foam	Arcutis Biotherapeutics, Inc.	phase 3	Phosphodiesterase-4 (PDE-4) inhibitor	PDE-4
Roflumilast Foam 0.3%	Roflumilast Foam 0.3%	Arcutis Biotherapeutics, Inc.	phase 3	Phosphodiesterase-4 (PDE-4) inhibitor	PDE-4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Phosphodiesterase-4 (PDE-4) inhibitor class)

Arcutis Biotherapeutics, Inc. · 3 drugs in this class
Amgen · 1 drug in this class
Asan Medical Center · 1 drug in this class
The University of Hong Kong · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oral roflumilast — Competitive Intelligence Brief. https://druglandscape.com/ci/oral-roflumilast. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab